Paul Talmo Purchases 22,222 Shares of TELA Bio, Inc. (NASDAQ:TELA) Stock

TELA Bio, Inc. (NASDAQ:TELA) CTO Paul Talmo acquired 22,222 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The shares were bought at an average price of $2.25 per share, with a total value of $49,999.50. Following the completion of the purchase, the chief technology officer now directly owns 91,082 shares in the company, valued at $204,934.50. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

TELA Bio Stock Up 10.9 %

NASDAQ:TELA opened at $2.86 on Friday. The company has a current ratio of 3.41, a quick ratio of 2.52 and a debt-to-equity ratio of 14.22. TELA Bio, Inc. has a twelve month low of $2.30 and a twelve month high of $7.84. The company has a market cap of $70.51 million, a PE ratio of -1.71 and a beta of 0.99. The company’s 50 day moving average is $2.67 and its two-hundred day moving average is $4.15.

TELA Bio (NASDAQ:TELA) last issued its earnings results on Monday, August 12th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.06). TELA Bio had a negative return on equity of 252.57% and a negative net margin of 65.04%. The business had revenue of $16.09 million for the quarter, compared to analysts’ expectations of $19.00 million. During the same period last year, the business earned ($0.46) EPS. Analysts anticipate that TELA Bio, Inc. will post -1.39 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have commented on TELA shares. Canaccord Genuity Group reissued a “buy” rating and set a $12.00 price target on shares of TELA Bio in a research report on Friday, October 4th. JMP Securities reduced their price target on TELA Bio from $15.00 to $12.00 and set a “market outperform” rating on the stock in a research report on Tuesday, August 13th. Piper Sandler decreased their price objective on TELA Bio from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, August 13th. Finally, Lake Street Capital dropped their target price on TELA Bio from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th.

Institutional Investors Weigh In On TELA Bio

Several institutional investors have recently bought and sold shares of the company. Point72 DIFC Ltd acquired a new stake in TELA Bio in the 2nd quarter valued at about $25,000. Embree Financial Group acquired a new stake in shares of TELA Bio during the 3rd quarter worth about $25,000. Ground Swell Capital LLC purchased a new stake in shares of TELA Bio in the 2nd quarter valued at approximately $53,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in TELA Bio in the second quarter valued at approximately $115,000. Finally, Los Angeles Capital Management LLC purchased a new position in shares of TELA Bio during the second quarter worth $131,000. 94.35% of the stock is currently owned by institutional investors and hedge funds.

TELA Bio Company Profile

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.